Skip to main content

Table 2 Baseline characteristics of participants in REPAIR-MS (n = 11)

From: Evidence of brain target engagement in Parkinson’s disease and multiple sclerosis by the investigational nanomedicine, CNM-Au8, in the REPAIR phase 2 clinical trials

Baseline Participant Demographics

 

Age (years)

41.6 ± 10.0

BMI (kg/m2)

27.9 ± 5.7

Sex (% Female)

69%

Race/ethnicity, non-Hispanic White (%)

85%

Age at diagnosis (years)

34.5 ± 9.4

Time from symptom onset at enrollment (years)

7.1 ± 4.6

Time since last relapse (years)

4.5 ± 3.2

% Treated with natalizumab

100%

EDSS Score

2.7 ± 1.9

  1. Values given are mean ± standard deviation.